These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 15031627

  • 1. Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model.
    Zhou X, Ono H, Ono Y, Frohlich ED.
    Am J Nephrol; 2004; 24(2):242-9. PubMed ID: 15031627
    [Abstract] [Full Text] [Related]

  • 2. N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model.
    Zhou X, Ono H, Ono Y, Frohlich ED.
    J Hypertens; 2002 May; 20(5):993-1000. PubMed ID: 12011661
    [Abstract] [Full Text] [Related]

  • 3. Superiority of combination of thiazide with angiotensin-converting enzyme inhibitor or AT1-receptor blocker over thiazide alone on renoprotection in L-NAME/SHR.
    Zhou X, Matavelli LC, Ono H, Frohlich ED.
    Am J Physiol Renal Physiol; 2005 Oct; 289(4):F871-9. PubMed ID: 15900021
    [Abstract] [Full Text] [Related]

  • 4. ACE inhibition prevents and reverses L-NAME-exacerbated nephrosclerosis in spontaneously hypertensive rats.
    Ono H, Ono Y, Frohlich ED.
    Hypertension; 1996 Feb; 27(2):176-83. PubMed ID: 8567038
    [Abstract] [Full Text] [Related]

  • 5. Hydrochlorothiazide exacerbates nitric oxide-blockade nephrosclerosis with glomerular hypertension in spontaneously hypertensive rats.
    Ono Y, Ono H, Frohlich ED.
    J Hypertens; 1996 Jul; 14(7):823-8. PubMed ID: 8818920
    [Abstract] [Full Text] [Related]

  • 6. Angiotensin type 1 receptor antagonism and ACE inhibition produce similar renoprotection in N(omega)-nitro-L>-arginine methyl ester/spontaneously hypertensive rats.
    Nakamura Y, Ono H, Zhou X, Frohlich ED.
    Hypertension; 2001 May; 37(5):1262-7. PubMed ID: 11358938
    [Abstract] [Full Text] [Related]

  • 7. Calcium antagonist inhibits glomerular cell apoptosis and injuries of L-NAME exacerbated nephrosclerosis in SHR.
    Watanabe S, Ono H, Ishimitsu T, Matsuoka H, Ono Y, Fujimori T.
    Hypertens Res; 2000 Nov; 23(6):683-91. PubMed ID: 11131282
    [Abstract] [Full Text] [Related]

  • 8. The antagonism of aldosterone receptor prevents the development of hypertensive heart failure induced by chronic inhibition of nitric oxide synthesis in rats.
    Tsukamoto O, Minamino T, Sanada S, Okada K, Hirata A, Fujita M, Shintani Y, Yulin L, Asano Y, Takashima S, Yamasaki S, Tomoike H, Hori M, Kitakaze M.
    Cardiovasc Drugs Ther; 2006 Apr; 20(2):93-102. PubMed ID: 16761190
    [Abstract] [Full Text] [Related]

  • 9. Combination therapy with telmisartan and spironolactone alleviates L-NAME exacerbated nephrosclerosis with an increase in PPAR-gamma and decrease in TGF-beta(1).
    Takahashi T, Ono H, Ono Y, Ishimitsu T, Matsuoka H.
    Int Heart J; 2007 Sep; 48(5):637-47. PubMed ID: 17998773
    [Abstract] [Full Text] [Related]

  • 10. Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading.
    Martinez DV, Rocha R, Matsumura M, Oestreicher E, Ochoa-Maya M, Roubsanthisuk W, Williams GH, Adler GK.
    Hypertension; 2002 Feb; 39(2 Pt 2):614-8. PubMed ID: 11882618
    [Abstract] [Full Text] [Related]

  • 11. Effect of ramipril alone compared to ramipril with eplerenone on diabetic nephropathy in streptozocin-induced diabetic rats.
    Mavrakanas TA, Cheva A, Kallaras K, Karkavelas G, Mironidou-Tzouveleki M.
    Pharmacology; 2010 Feb; 86(2):85-91. PubMed ID: 20689340
    [Abstract] [Full Text] [Related]

  • 12. Effects of eplerenone on heart and kidney in two-kidney, one-clip rats.
    Hao L, Kanno Y, Fukushima R, Watanabe Y, Ishida Y, Suzuki H.
    Am J Nephrol; 2004 Feb; 24(1):54-60. PubMed ID: 14707436
    [Abstract] [Full Text] [Related]

  • 13. Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats.
    Du J, Fan YY, Hitomi H, Kiyomoto H, Kimura S, Kong CZ, Noma T, Kohno M, Nishiyama A, Nakano D.
    Am J Physiol Renal Physiol; 2009 Sep; 297(3):F802-8. PubMed ID: 19535572
    [Abstract] [Full Text] [Related]

  • 14. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo.
    Brown NJ, Nakamura S, Ma L, Nakamura I, Donnert E, Freeman M, Vaughan DE, Fogo AB.
    Kidney Int; 2000 Sep; 58(3):1219-27. PubMed ID: 10972684
    [Abstract] [Full Text] [Related]

  • 15. Imidapril improves L-NAME-exacerbated nephrosclerosis with TGF-beta 1 inhibition in spontaneously hypertensive rats.
    Ono H, Saitoh M, Ono Y, Ishimitu T, Matsuoka H.
    J Hypertens; 2004 Jul; 22(7):1389-95. PubMed ID: 15201556
    [Abstract] [Full Text] [Related]

  • 16. Differential effects of T- and L-type calcium antagonists on glomerular dynamics in spontaneously hypertensive rats.
    Nakamura Y, Ono H, Frohlich ED.
    Hypertension; 1999 Aug; 34(2):273-8. PubMed ID: 10454453
    [Abstract] [Full Text] [Related]

  • 17. Developmental activity of the renin-angiotensin system during the "critical period" modulates later L-NAME-induced hypertension and renal injury.
    Ishiguro K, Sasamura H, Sakamaki Y, Itoh H, Saruta T.
    Hypertens Res; 2007 Jan; 30(1):63-75. PubMed ID: 17460373
    [Abstract] [Full Text] [Related]

  • 18. Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome.
    Nakhoul F, Khankin E, Yaccob A, Kawachi H, Karram T, Awaad H, Nakhoul N, Hoffman A, Abassi Z.
    Am J Physiol Renal Physiol; 2008 Mar; 294(3):F628-37. PubMed ID: 18094029
    [Abstract] [Full Text] [Related]

  • 19. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors.
    Nagase M, Yoshida S, Shibata S, Nagase T, Gotoda T, Ando K, Fujita T.
    J Am Soc Nephrol; 2006 Dec; 17(12):3438-46. PubMed ID: 17082236
    [Abstract] [Full Text] [Related]

  • 20. [The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? ].
    Morales E, Huerta A, Gutiérrez E, Gutiérrez Solís E, Segura J, Praga M.
    Nefrologia; 2009 Dec; 29(5):421-9. PubMed ID: 19820754
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.